Cerbomed opens up new markets: From March on t-VNS with NEMOS will be available in Italy for the treatment of epilepsies

  Cerbomed opens up new markets: From March on t-VNS with NEMOS will be
  available in Italy for the treatment of epilepsies

Business Wire

ERLANGEN, Germany -- February 21, 2013

More than 500,000 patients suffer from epilepsy in Italy. Not all of them can
be treated sufficiently with available anticonvulsive medication. Therefore
the medical device company cerbomed GmbH from Erlangen, Germany, announces
that, from March 2013 on, transcutaneous vagus nerve stimulation (t-VNS) with
NEMOS will be available to Italian epilepsy patients. To address the Italian
market, cerbomed is cooperating with MARVAMED, a medical devices sales
specialist experienced in the Italian neurology market. This is the first,
successful step in extending into new European markets. Cooperations with
further European distributors should follow in the course of the year.

MARVAMED's managing director, Dr. Pierluigi Bertolotto, has more than 20
years’ experience in neuromodulation and neurosurgery. He has both technical
know-how and a network with experts in the field of epilepsy. His company,
MARVAMED, based in Genoa, is a distributor specializing in medical products
for neuromodulation and functional neurosurgery. "Hard-to-treat epilepsy
patients suffer severely, and currently there are only a few therapy
alternatives. I am glad to announce that with the transcutaneous vagus nerve
stimulator NEMOS, a promising therapy option is now available in Italy, too",
Bertolotto declares.

"We are happy to cooperate with MARVAMED. Such an effective and experienced
sales partner will let us offer t-VNS with NEMOS to patients in Italy", says
Dr. Andreas Hartlep, Chief Executive Officer of cerbomed GmbH.

About t-VNS with NEMOS

Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from
various difficult-to-treat neurological and psychiatric diseases. The t-VNS
therapy uses the fact that a branch of the vagus nerve is located directly
under the skin in areas of the outer ear and therefore can be stimulated
through the skin (transcutaneously) with electrical impulses.

With NEMOS cerbomed developed and patented a special stimulator and a
dedicated ear electrode for treatment of epilepsies with t-VNS. The
stimulator, which is connected with the ear electrode, sends out the
electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a
targeted stimulation of the vagus nerve gets possible without the need of a
surgery.

About cerbomed

Cerbomed GmbH is an innovative medical device company located in Erlangen,
Germany, that focuses on neuromodulation. The company, founded in 2005,
focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an
attractive therapy option for patients with hard-to-treat neurological and
psychiatric illnesses.

In 2010 cerbomed received the European clearance (CE mark) for the
transcutaneous Vagus Nerve Stimulation for the treatment of epilepsies and
depression, in 2012 for the treatment of pain.

Currently two clinical studies are carried out regarding the effectiveness of
t-VNS in patients with drug-resistant epilepsy and chronic migraine.

In September 2012 cerbomed entered into a strategic partnership with
Cyberonics, Inc., the global market leader in vagus nerve stimulation.

NEMOS is already available for treating epilepsies in Germany and Austria, and
in Italy from March 2013. Forthcoming cooperations with other distributors
should make NEMOS available to epilepsy patients in Great Britain, France and
Spain.

Please visit us on www.cerbomed.com.

About MARVAMED

MARVAMED, based in Genoa, is a distributor specializing in medical products
for neuromodulation and functional neurosurgery. The company was founded in
March 2010 by Dr. Pierluigi Bertolotto, who has 20 years of experience in the
neurology market, in the area of movement disturbances and pain.

Contact:

Dr. Martin Hyca, Director Marketing & Sales
cerbomed GmbH
Phone: 0049 9131 9202 76 30
martin.hyca@cerbomed.com
or
Dr. Pierluigi Bertolotto, CEO
MARVAMED
Phone: 0039 335481087
bertolotto@marvamed.com